TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3465787
Drug: Acetaminophen 1,000
Normalized name: Acetaminophen 1,000mg/30mL Oral solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen 1,000 mg before surgery
Study: 3465787
Drug: Acetaminophen 650
Normalized name: acetaminophen 650 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen 650 mg administered at fixed intervals after surgery
Study: 3465787
Drug: Acetaminophen 1,000
Normalized name: Acetaminophen 1,000mg/30mL Oral solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen 1,000 mg before surgery with acetaminophen as needed after surgery
Study: 30868491
Drug: Unchanged pharmacological
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unchanged pharmacological anti-arrhythmia therapy
Study: 26873501
Drug: Low-level laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level laser therapy (LLLT) - 2 sessions weekly for 5 weeks, using a 980-nm AlGaAs diode laser at 300 mW, delivering a Fluence of 10 J/cm²
Study: 26873501
Drug: Clonazepam -
Normalized name: Clonazepam
DrugBank: Clonazepam (DB01068)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clonazepam - half a tablet (2 mg) in the mouth for 3 min, three times a day for 21 days
Study: 17620074
Drug: Sublingual immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual immunotherapy (SLIT) with 200,000 SQ-U
Study: 17620074
Drug: Sublingual immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual immunotherapy (SLIT) with 24,000 SQ-U
Study: 16238883
Drug: Cognitive-behavioural anger
Normalized name: After banger
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cognitive-behavioural anger treatment (AT group)
Study: 7605855
Drug: Cisapride (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisapride (10 mg) without gastritis
Study: 7605855
Drug: Cisapride (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisapride (10 mg) with normal gastric emptying
Study: 7324888
Drug: Paraffin‐based neutral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paraffin‐based neutral eye ointment Ph. Nord. 63
Study: 21835452
Drug: GnRH (0.004
Approvals — FDA: no, EMA: no, PMDA: no
Description: GnRH (0.004 mg buserelin)
Study: 19421185
Drug: Odanacatib (ODN)
Normalized name: Odanacatib
DrugBank: Odanacatib (DB06670)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Odanacatib (ODN) once weekly for 3 weeks
Study: 19421185
Drug: Odanacatib (ODN)
Normalized name: Odanacatib
DrugBank: Odanacatib (DB06670)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Odanacatib (ODN) once daily for 21 days
Study: 19421185
Drug: Odanacatib (ODN)
Normalized name: Odanacatib
DrugBank: Odanacatib (DB06670)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Odanacatib (ODN) at weekly doses > or = 25 mg
Study: 19421185
Drug: Odanacatib (ODN)
Normalized name: Odanacatib
DrugBank: Odanacatib (DB06670)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Odanacatib (ODN) at daily doses > or = 2.5 mg
Study: 15145970
Drug: M100240 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: M100240 50 mg once daily
Study: 15145970
Drug: M100240 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: M100240 25 mg three times daily or 50 mg twice daily
Study: 15145970
Drug: M100240 up
Normalized name: Q-Up
Approvals — FDA: no, EMA: no, PMDA: no
Description: M100240 up to 50 mg once daily
Study: 11586054
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg trazodone
Study: 7758394
Drug: Arbekacin (ABK)
Normalized name: arbekacin
DrugBank: Arbekacin (DB06696)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arbekacin (ABK) in combination with other compounds
Study: 7758394
Drug: Arbekacin (ABK)
Normalized name: arbekacin
DrugBank: Arbekacin (DB06696)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arbekacin (ABK) in patients pretreated with other drugs
Study: 28914446
Drug: Concomitant use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concomitant use of biologic drugs
Study: 25943574
Drug: Doublet chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doublet chemotherapy (FOLFOX or FOLFIRI) plus bevacizumab
Study: 25943574
Drug: Doublet chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doublet chemotherapy (FOLFOX or FOLFIRI) plus panitumumab
Study: 25943574
Drug: Triple chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple chemotherapy (FOLFOXIRI) plus bevacizumab
Study: 18261575
Drug: Alendronate +
Normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alendronate + Alfacalcidol (10 mg/d + 0.5 microg/d)
Study: 6091392
Drug: Misonidazole (11
Approvals — FDA: no, EMA: no, PMDA: no
Description: Misonidazole (11 g/m2 over four weeks)
Study: 26081039
Drug: Rinsing with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rinsing with 15 ml of water for 30 seconds
Study: 26081039
Drug: Drinking 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drinking 200 ml of water within 30 seconds
Study: 24801218
Drug: PF‐04447943 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF‐04447943 25 mg q12h
Study: 16209244
Drug: Music therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Music therapy (15 min duration)
Study: 16209244
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (without music therapy)
Study: 10336918
Drug: Sublingual glyceryl
Normalized name: glyceryl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual glyceryl trinitrate
Study: 10336918
Drug: Sequential use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential use of tests
Study: 2149280
Drug: Toremifene 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Toremifene 200 mg/day
Study: 2149280
Drug: Toremifene 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Toremifene 400 mg/day
Study: 2149280
Drug: Toremifene (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Toremifene (various doses)
Study: 2149280
Drug: Toremifene (doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Toremifene (doses >= 40 mg/day)
Study: 2149280
Drug: Toremifene (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Toremifene (all doses tested)
Study: 2149280
Drug: Toremifene (doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Toremifene (doses >= 60 mg/day)
Study: 7307428
Drug: Methadone (7.5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methadone (7.5, 15, or 30 mg/70 kg)
Study: 24880619
Drug: Intraorbital injections
Normalized name: zinc oxide
DrugBank: Zinc oxide (DB09321)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraorbital injections of rituximab (RTX)
Study: 24880619
Drug: Intravenous glucocorticoids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous glucocorticoids (GCs)
Study: 22737998
Drug: Intravitreal ranibizumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal ranibizumab injection (0.05 mL)
Study: 19836952
Drug: Aromatase inhibitors
Normalized name: Aromatase inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aromatase inhibitors (specific dosage and duration not mentioned)
Study: 12926979
Drug: Topical agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical agents (aluminum chloride) and iontophoresis
Study: 9133133
Drug: Oral polyethylene
Normalized name: polyethylenes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral polyethylene glycol solution (Fordtran)
Study: 8363995
Drug: tropisetron (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: tropisetron (5 mg/day; n = 115)
Study: 8363995
Drug: optimal standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: optimal standard therapy (n = 116)
Study: 20205490
Drug: Sitagliptin as
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitagliptin as initial combination therapy with metformin or pioglitazone
Study: 20205490
Drug: Sitagliptin add-on
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitagliptin add-on therapy
Study: 20205490
Drug: Sitagliptin as
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitagliptin as add-on treatment to metformin
Study: 20205490
Drug: Sitagliptin as
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitagliptin as add-on treatment to pioglitazone
Study: 11878736
Drug: 2% lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% lidocaine with 1:200,000 epinephrine and hyaluronidase 150 U ml(‐1) in a volume of 4 or 5 ml
Study: 9779169
Drug: Prolonged antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged antibiotics (Unasyn and Aztreonam)
Study: 9779169
Drug: Perioperative antibiotics
Normalized name: ENSURE SURGERY PERIOPERATIVE KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perioperative antibiotics only (Unasyn)
Study: 8154635
Drug: RG 12525
Normalized name: DNA, D((2'-O-(2-METHOXYETHYL))M5RC-SP-(2'-O-(2-METHOXYETHYL))RA-(2'-O-(2-METHOXYETHYL))RG-SP-(2'-O-(2-METHOXYETHYL))RG-(2'-O-(2-METHOXYETHYL))RA-SP-T-SP-A-SP-M5C-SP-A-SP-T-SP-T-SP-T-SP-M5C-SP-T-SP-A-SP-(2'-O-(2-METHOXYETHYL))M5RC-(2'-O-(2-METHOXYETHYL))R
Approvals — FDA: no, EMA: no, PMDA: no
Description: RG 12525 200 mg
Study: 8154635
Drug: RG 12525
Normalized name: DNA, D((2'-O-(2-METHOXYETHYL))M5RC-SP-(2'-O-(2-METHOXYETHYL))RA-(2'-O-(2-METHOXYETHYL))RG-SP-(2'-O-(2-METHOXYETHYL))RG-(2'-O-(2-METHOXYETHYL))RA-SP-T-SP-A-SP-M5C-SP-A-SP-T-SP-T-SP-T-SP-M5C-SP-T-SP-A-SP-(2'-O-(2-METHOXYETHYL))M5RC-(2'-O-(2-METHOXYETHYL))R
Approvals — FDA: no, EMA: no, PMDA: no
Description: RG 12525 25 mg
Study: 3163364
Drug: Low fat
Normalized name: Low fat spread
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low fat (31% of total kcal)/low cholesterol (193 mg/d) (LFLC)
Study: 3163364
Drug: Low fat/usual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low fat/usual cholesterol (504 mg/d) (LFUC)
Study: 30246150
Drug: Metoclopramide (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide (10 mg thrice daily)
Study: 30246150
Drug: Ceftriaxone (2000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone (2000 mg once daily)
Study: 30246150
Drug: Paracetamol (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol (1000 mg four times daily)
Study: 30246150
Drug: Any combination
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Any combination of metoclopramide, ceftriaxone, paracetamol
Study: 27176931
Drug: Surgery +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgery + Postoperative Radiotherapy (PORT) (median dose: 45 Grays)
Study: 18771643
Drug: SPL7013 Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: SPL7013 Gel
Study: 16520686
Drug: Modafinil (100-400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modafinil (100-400 mg/day, median stable dose 300 mg/day)
Study: 11145438
Drug: Interferon as
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon as maintenance after high-dose chemotherapy with stem cell support (NMSG 5/94)
Study: 9181655
Drug: Tobramycin 160
Normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tobramycin 160 mg i.v. once daily for 2 days + Cefotaxime 1 g i.v. twice daily for 2 days followed by oral Cefadroxil 1 g twice daily for 10 days
Study: 9181655
Drug: Cefotaxime 1
Normalized name: cefotaxime 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefotaxime 1 g i.v. twice daily for 2 days followed by oral Cefadroxil 1 g twice daily for 10 days
Study: 3535021
Drug: CBS coated
Normalized name: BroveX CB
Approvals — FDA: no, EMA: no, PMDA: no
Description: CBS coated tablets
Study: 3535021
Drug: CBS chewing
Normalized name: BroveX CB
Approvals — FDA: no, EMA: no, PMDA: no
Description: CBS chewing tablets
Study: 3535021
Drug: CBS coated
Normalized name: BroveX CB
Approvals — FDA: no, EMA: no, PMDA: no
Description: CBS coated tablets and CBS chewing tablets
Study: 27733181
Drug: Innovative psychological
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Innovative psychological therapy for depression (REFRAMED)
Study: 22889722
Drug: Antidepressants (TCAs)
Normalized name: ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressants (TCAs)
Study: 22889722
Drug: Antidepressants (Miscellaneous)
Normalized name: ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressants (Miscellaneous)
Study: 10097932
Drug: Cyclosporine A
Normalized name: CycloSPORINE A
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine A (CsA) at an initial dosage of 9.3 mg.kg‐1.day‐1 tapered to 7.0 mg.kg‐1.day‐1 for 12.5 +/- 4.0 months
Study: 1768544
Drug: Magnesium sulphate
Normalized name: Magnesium sulphate
DrugBank: Magnesium (DB14513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium sulphate 30 mg kg‐1 with alfentanil 7.5 micrograms kg‐1
Study: 1768544
Drug: Magnesium sulphate
Normalized name: Magnesium sulphate
DrugBank: Magnesium (DB14513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium sulphate 40 mg kg‐1 and Magnesium sulphate 30 mg kg‐1 with alfentanil 7.5 micrograms kg‐1
Study: 31738342
Drug: Rotavirus Vaccine
Normalized name: rotavirus vaccine
DrugBank: Rotavirus vaccine (DB10276)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rotavirus Vaccine (RVV)
Study: 28317676
Drug: Levofloxacin 1.5%
Normalized name: LEVOFLOXACIN 1.5% OPH SOLN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levofloxacin 1.5% ophthalmic solution for 1 week postoperative
Study: 28317676
Drug: Levofloxacin 1.5%
Normalized name: LEVOFLOXACIN 1.5% OPH SOLN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levofloxacin 1.5% ophthalmic solution for 1 month postoperative
Study: 24634627
Drug: Bilateral BoNT‐A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilateral BoNT‐A injections (25 U per muscle) into the masseter muscles only (group A)
Study: 24634627
Drug: Bilateral BoNT‐A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilateral BoNT‐A injections into both the masseter and temporalis muscles (group B)
Study: 22865871
Drug: Low-dose oral
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose oral prednisolone (0.5 mg/kg) for 3 days
Study: 22865871
Drug: High-dose oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose oral prednisolone (2 mg/kg) for 3 days
Study: 17442556
Drug: BacoMind (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: BacoMind (300 mg for first 15 days, 450 mg for next 15 days)
Study: 11193245
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg E2V + 2.5 mg MPA
Study: 11193245
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg E2V + 5 mg MPA
Study: 11193245
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg E2V + 2.5 mg MPA
Study: 11193245
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg E2V + 5 mg MPA
Study: 11193245
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg E2V increased to 2 mg after 6 months + 2.5 mg MPA
Study: 11193245
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg E2V increased to 2 mg after 6 months + 5 mg MPA
Study: 11193245
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg MPA
Study: 11193245
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg MPA
Study: 31315728
Drug: Transcutaneous neuromuscular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcutaneous neuromuscular electrical stimulation (twice a day, 30 minutes each time)
Study: 15936036
Drug: Mannitol 20%,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mannitol 20%, 100 ml every 4 h for 5 days, tapered in the next 2 days
Study: 12796019
Drug: FAC (doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: FAC (doxorubicin 500 mg/m², cyclophosphamide 50 mg/m², fluorouracil 500 mg/m²) every 3 weeks for six cycles
Study: 12796019
Drug: CMF (methotrexate
Approvals — FDA: no, EMA: no, PMDA: no
Description: CMF (methotrexate 600 mg/m², cyclophosphamide 60 mg/m², fluorouracil 600 mg/m²) every 3 weeks for six cycles
Study: 1888619
Drug: Individualised drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individualised drug information wallet (leaflet group)
Study: 30196448
Drug: 0.3 g
Normalized name: sorbitol 0.3 GM Oral Lozenge
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 g kg‐1 BM NaHCO3 (SBC3)
Study: 30196448
Drug: 0.2 g
Normalized name: methionine 0.2 gram ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 g kg‐1 BM NaHCO3 (SBC2)
Study: 27550876
Drug: Levofloxacin 500
Normalized name: levofloxacin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levofloxacin 500 mg once a day for 3 days after UDS
Study: 24877603
Drug: CHoR protocol
Normalized name: Olay Professional Acne Protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHoR protocol (preoperative erythropoietin and iron therapy, intraoperative blood recycling device, lower hemoglobin trigger < 7 g/dl)
Study: 22369484
Drug: Repeated near-infrared
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeated near-infrared (NIR) light irradiation with fractionated administration of panitumumab-IR700 conjugate
Study: 19808265
Drug: Nesiritide (2-microg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nesiritide (2-microg/kg bolus plus 0.01-microg/kg-per-minute infusion for 4 to 6 hours, once or twice weekly for 12 weeks)
Study: 19808265
Drug: Placebo (matching
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (matching placebo, once or twice weekly for 12 weeks)
Study: 16060245
Drug: Endovascular therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular therapy for unruptured cerebral aneurysms
Study: 16060245
Drug: Endovascular therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular therapy for aneurysms between 5 to 10 mm
Study: 16060245
Drug: Endovascular therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular therapy for aneurysms between 11 to 25 mm
Study: 16060245
Drug: Endovascular therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular therapy for aneurysms smaller than 5 mm
Study: 16060245
Drug: Endovascular therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular therapy for aneurysms between 5 to 10 mm (follow-up)
Study: 16060245
Drug: Endovascular therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular therapy for aneurysms between 10 to 24 mm (follow-up)
Study: 16060245
Drug: Endovascular therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular therapy overall
Study: 16060245
Drug: Endovascular therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular therapy for a large basilar tip aneurysm
Study: 6294004
Drug: Increased carbohydrate
Normalized name: pyrrolidone carboxylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increased carbohydrate intake from 200 to 400 g
Study: 6294004
Drug: Increase of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increase of dietary fibre to 50 g mainly as cereal fibre
Study: 22057652
Drug: Thiamine (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiamine (300 mg/day)
Study: 19605370
Drug: Type I
Normalized name: collagen type I
Approvals — FDA: no, EMA: no, PMDA: no
Description: Type I oral collagen
Study: 16755104
Drug: Extended adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended adjuvant therapy, selection of responders using array-based techniques, combination therapy with signal transduction inhibitors
Study: 10992952
Drug: Daily practice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily practice of three visual tasks (fixation, saccade, and distractor conditions) for 3 to 8 weeks
Study: 8865709
Drug: 150 ml
Normalized name: REBYOTA 150 ML Enema
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 ml oral water
Study: 8865709
Drug: 150 ml
Normalized name: REBYOTA 150 ML Enema
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 ml refreshing drink
Study: 1624025
Drug: Leuprolide acetate
Normalized name: Leuprolide Acetate
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leuprolide acetate 1.88 mg
Study: 6084920
Drug: Increased concentration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increased concentration of IgE antibodies
Study: 6084920
Drug: Specific IgG
Normalized name: Mold specific IgG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specific IgG antibodies towards TR
Study: 6084920
Drug: Presence of
Normalized name: Dna Plasmid Expressing Diphtheria Toxin Triggered By The Presence Of Oncofetal Gene H19
DrugBank: Inodiftagene vixteplasmid (DB16017)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Presence of specific IgG antibodies and strong specific cellular immune response
Study: 28118549
Drug: Lower-target group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower-target group (80 to 110 mg/dL)
Study: 28118549
Drug: Higher-target group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher-target group (150 to 180 mg/dL)
Study: 26009989
Drug: 3 weeks
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 weeks of oral antibiotic treatment
Study: 26009989
Drug: 6 weeks
Normalized name: perampanel
DrugBank: Perampanel (DB08883)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 6 weeks of oral antibiotic treatment
Study: 21757386
Drug: Control periodontal
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control periodontal therapy (CPT)
Study: 21757386
Drug: Intensive periodontal
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive periodontal therapy (IPT) in type 2 DM
Study: 14747190
Drug: GnRH analogue
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH analogue (3.75 mg/28 days leuprolide acetate depot) with raloxifene (60 mg/day)
Study: 2898025
Drug: Intensified diabetic
Normalized name: Diabetic Tussin EX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensified diabetic control with continuous subcutaneous insulin infusion (CSII)
Study: 30370503
Drug: Hypothetical above
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypothetical above average pharmacogenetic response to smoking cessation medication
Study: 30370503
Drug: Hypothetical below
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypothetical below average pharmacogenetic response to smoking cessation medication
Study: 28969404
Drug: Green tea
Normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Green tea catechins (600 mg daily for 1 year)
Study: 26242893
Drug: Intravenous ibandronate
Normalized name: ibandronate
DrugBank: Ibandronate (DB00710)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ibandronate (6mg)